Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis With Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial. J of Skin 2021, 5 (1), s18. https://doi.org/10.25251/skin.5.supp.18.